Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The European Commission has approved Pfizer Inc's (NYSE:PFE) Lorviqua (lorlatinib) for a form of advanced non-small-cell lung cancer (NSCLC).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Lorlatinib is available in the U.S. under the brand name Lorbrena.
- The approval covers lorlatinib as monotherapy for anaplastic lymphoma kinase (ALK)- positive advanced NSCLC previously not treated with an ALK inhibitor.
- Related: Pfizer's Lorbrena Wins Full FDA Approval As First-Line Treatment Of ALK-Positive Lung Cancer.
- The approval for the first-line use is based on the pivotal Phase 3 CROWN trial results, in which Lorviqua reduced the risk of disease progression or death by 72% compared to Xalkori (crizotinib).
- As a secondary endpoint, the confirmed objective response rate (ORR) was 76% with Lorviqua and 58% with Xalkori.
- Price Action: PFE shares are up 2.16% at $54.52 during the market session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.